CD38 and allergic rhinitis: Interestingly, TL, which was approved decades ago for the treatment of inflammatory diseases (e.g. bronchial asthma, allergic rhinitis) with remarkable success31, could be targeting the CD38/cADPR pathway by down-regulating CD38 expression.